GentiBio starts a Phase-I Clinical Trial on GNTI-122 in Honeymooners (POLARIS)

GentiBio, Inc. is sponsoring a clinical trial known as POLARIS, which aims to evaluate a cell therapy called GNTI-122 in honeymoon adults. It is created specifically for each participant using their own blood cells. GNTI-122 is administered as a single dose. GNTI-122 is designed to modify regulatory T cells - immune cells that help prevent the body from attacking its own tissues. By enhancing the…